Delivery Order SPE2DR25D1053-SPE2DR26FV283
- Not listed
- The Defense Logistics Agency awarded a delivery order to Amerisourcebergen Drug Corp (subsidiary of Cencora, Inc.) on January 6, 2026, for the supply of ORGOVYX 120 MG tablets in quantities of 30 units, with a contract ceiling value of $2,920.26. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for supply of ORGOVYX 120 MG tablets in quantities of 30s, valued at $6,927.60 with a firm fixed price structure and completion deadline of September 29, 2025. This delivery order represents a non-set-aside, competitively awarded procurement under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count packages) on September 22, 2025, with completion targeted for October 14, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract is valued at $4,380.39 and carries a firm fixed price structure with an ultimate completion date of January 8, 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,460.13. This competitive delivery order, issued on December 30, 2025, with an ultimate completion date of January 22, 2026, utilizes firm fixed pricing and carries no set-aside designation. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $8,313.12 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit of use packaging). This firm fixed-price contract, with a completion date of September 25, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made through open competition...
- The Defense Logistics Agency awarded a delivery order valued at $8,760.78 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) on November 13, 2025, with completion scheduled for December 5, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $8,313.12 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit dose) with an ultimate completion date of October 16, 2025. The contract is non-competitive with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This firm fixed-price delivery order, awarded on January 6, 2026, will be fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with a completion date of January 28, 2026. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to...
- The Defense Logistics Agency awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV283Delivery Order
On January 6, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 MG tablets (30-count units). This firm fixed-price, non-set-aside contract is scheduled for completion by January 28, 2026, with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a $999,999,999.00 ceiling value through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's DLA IDC enables it to supply a broad spectrum of pharmaceutical products and medical supplies—including brand-name and generic medications, vaccines, and specialized healthcare commodities—across multiple therapeutic domains. This delivery order for ORGOVYX, a specialized pharmaceutical treatment, reflects the company's capability to fulfill targeted federal medical supply requirements through the DLA's competitive pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 1/5/26 |